Review and management of drug interactions with boceprevir and telaprevir
Jennifer J. Kiser, James R. Burton, Peter L. Anderson, Gregory T. Everson – 13 February 2012 – Boceprevir (BOC) and telaprevir (TPV), when added to pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the rates of sustained virologic response in treatment‐naïve persons to approximately 70%. Though these agents represent an important advance in the treatment of chronic HCV, they present new treatment challenges to the hepatology community.